Bedrijfsoverzicht
Ernexa Therapeutics Inc. is a preclinical-stage biotechnology company dedicated to developing inducible mesenchymal stem cell (iMSC) therapies designed to treat cancer and autoimmune diseases. The firm operates within the healthcare sector, specifically focusing on the biotechnology industry, where its primary objective is the advancement of allogenic pro-inflammatory cytokine secreting cells, such as the lead product ERNA-101, for therapeutic application. As of the latest available data, the company maintains a market capitalization of $5.69M and employs a staff of 5 individuals to execute its research and development initiatives. The combination of a $5.69M market cap, N/A annual revenue, and a workforce of 5 employees indicates that Ernexa is a micro-cap entity with a very early-stage operational scale. This valuation profile suggests the company is still in the fundamental research phase, where value is derived from intellectual property and pipeline potential rather than established commercial cash flows or significant revenue generation.
Financiële gezondheid
The company reported N/A revenue and a net income of $-14,100,000 over the trailing twelve-month period, while EBITDA stood at $-9,254,000. The substantial gap between the N/A revenue figure and the significant net loss reveals a cost structure heavily weighted toward research, development, and operational overheads typical of preclinical-stage biotechnology firms that have not yet achieved commercial sales milestones. Free cash flow was recorded at $-4,576,250, which indicates that the company is consuming its existing cash reserves to fund its operations and development activities rather than generating liquidity from its business. Despite the negative cash flow, the company holds $1.88M in cash against $490,000 in debt, resulting in a debt-to-equity ratio of 20.41 that characterizes a highly leveraged balance sheet relative to its equity base, though the absolute debt amount remains modest in dollar terms. The current ratio is 1.01, which suggests that the company's short-term liquid assets are just sufficient to cover its current liabilities, leaving little margin for error regarding immediate liquidity needs. Return on Equity is -686.7% and Return on Assets is -104.9%, metrics that mathematically reflect the company's stage of development where expenses significantly outweigh any potential earnings, indicating that management effectiveness is currently measured by the pace of pipeline progression rather than profitability.
Waarderingsbeoordeling
The P/E Ratio (TTM) is listed as N/A due to the lack of positive earnings, while the Forward P/E is calculated at -0.02, implying that the market is pricing in future earnings recovery or that the current valuation is based entirely on asset and pipeline value rather than historical profitability. The price-to-book ratio stands at 0.64, which indicates that the company is currently trading at a discount to its net asset value, a common characteristic for early-stage biotechnology firms where the book value does not fully capture the potential value of the drug pipeline. Alternative valuation metrics such as the Price to Sales ratio, which is N/A, and the EV/EBITDA of -0.46, further suggest that traditional valuation multiples are not applicable, as the enterprise value is negative relative to earnings before interest, taxes, depreciation, and amortization. The stock has experienced significant volatility within the recent trading year, with a 52-Week High of $4.05 and a 52-Week Low of $0.18, meaning the current price sits significantly below the recent peak and reflects the high-risk nature of the asset class. The Beta is 6.85, a figure that demonstrates extreme price volatility relative to the broader market, suggesting that the stock price is highly sensitive to sector-specific news, regulatory updates, or shifts in investor sentiment regarding biotechnology investments.
Growth & Income
The company recorded N/A revenue growth and N/A earnings growth year-over-year, reflecting the fact that it has not yet generated consistent commercial revenue streams to calculate growth rates. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, meaning the company retains all of its minimal earnings and cash flow to reinvest into its research and development efforts rather than distributing income to shareholders. This reinvestment strategy is standard for preclinical-stage companies where capital allocation focuses exclusively on advancing clinical trials and regulatory submissions to bring products to market. Consequently, the overall growth and income profile for Ernexa Therapeutics Inc. is characterized by a lack of current income generation and undefined historical growth metrics, relying entirely on future pipeline success to create shareholder value.